Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | GPR183 | P32249 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743604 | 0.79 | LMNA (0.46) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL278484 | 0.77 | LMNA (0.44) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14608744 | 0.75 | LMNA (0.42) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL19198810 | 0.71 | SLC6A4 (0.41) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8373572 | 0.71 | SLC6A4 (0.40) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12158829 | 0.71 | LMNA (0.44) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3755807 | 0.71 | SLC6A4 (0.41) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL14298073 | 0.70 | LMNA (0.42) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL8079753 | 0.70 | LMNA (0.42) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL7292734 | 0.70 | SLC6A4 (0.39) | LMNACYP2C9SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853599-B1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LTD (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-8334303-B2 | Specifically mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate (SB 268091); use as antibiotic; crystallization from isopropanol; improved bioavailability, and/or physical properties, for example solubility or flow properties | GLAZO GROUP LIMITED (GB) | 2012-12-18 | — | — | US | disclosed |
| US-8207191-B2 | Process, salts, composition and use | GLAXO GROUP LIMITED (GB) | 2012-06-26 | — | — | US | disclosed |
| US-20110144151-A1 | NOVEL PROCESS, SALTS, COMPOSITION AND USE | GLAXO GROUP LIMITED | 2011-06-16 | — | — | US | disclosed |
| US-7875630-B2 | reacting exo-8-methyl-8-azabicyclo[3.2.1]octan-3-thiol with mutilin 14-methanesulfonyloxyacetate in the presence of a tetra-n-butylammonium hydrogensulfate phase transfer catalyst, 4-methyl-2-pentanone, and aqueous NaOH to form mutilin 14-(exo-8-methyl-8-azabicyclo[3.2. 1]oct-3-ylsulfanyl)-acetate | GLAXO GROUP LIMITED | 2011-01-25 | — | — | US | disclosed |
| EP-2181995-A2 | Salts and crystalline form of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl-sufanyl)-acetate | Glaxo Group Limited (GB) | 2010-05-05 | — | — | EP | disclosed |
| EP-1663220-B1 | NOVEL PROCESS FOR THE PREPARATION OF PLEUROMUTILIN DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080161342-A1 | Novel Polymorph of Mutilin | GLAXO GROUP LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| EP-1853599-A1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LIMITED (GB) | 2007-11-14 | — | — | EP | disclosed |
| EP-1663220-A4 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LTD (GB) | 2007-04-18 | — | — | EP | disclosed |
| US-20060276503-A1 | Novel process salts compositions and use | GLAXO GROUP LIMITED | 2006-12-07 | — | — | US | disclosed |
| WO-2006092334-A1 | NOVEL POLYMORPH OF MUTILIN | GLAXO GROUP LIMITED (GB) | 2006-09-08 | — | — | WO | disclosed |
| EP-1663220-A1 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005023257-A1 | NOVEL PROCESS, SALTS, COMPOSITIONS AND USE | GLAXO GROUP LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144151-A1 | NOVEL PROCESS, SALTS, COMPOSITION AND USE | PLEC, MITF, MYOC | LMNA 3459/4885CYP2C9 3669/4885SLC6A4 2987/4885 |
| US-20080161342-A1 | Novel Polymorph of Mutilin | AMPD1, MSH2, MDN1 | LMNA 3721/4885CYP2C9 1019/4885SLC6A4 4175/4885 |
| US-20060276503-A1 | Novel process salts compositions and use | MYOC, MITF, MDN1 | LMNA 3623/4885CYP2C9 3868/4885SLC6A4 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.